Compugen Ltd..
CGEN.US | Research and experimental development on natural sciences and engineering
Compugen Ltd. is a clinical-stage drug discovery and development company focused on discovering and developing therapeutic products. The company utilizes its computational discovery platforms to identify novel drug targets and develop therapeutics in the field of immuno-oncology. Their primary focus...Show More
Better Health for All
50
Compugen Ltd. is a clinical-stage drug discovery and development company focused entirely on immuno-oncology and cancer treatment, meaning 100% of its core products and services are dedicated to delivering revolutionary health benefits. The company has no revenue from products with negative health outcomes, as its business model is exclusively focused on developing health-improving therapeutics.
1
All of Compugen's R&D expenses, which were $5.8 million in Q1 2025 and $6.3 million in Q3 2024, are allocated to health improvement, exceeding the >25% threshold for the highest score.
2
The company holds over 120 granted or pending patents, including a U.S. patent granted in 2025 covering triple combination use of COM902 for cancer treatment, which expires in August 2037.
3
Compugen is actively evaluating therapeutic antibodies in multiple clinical trials, including a Phase 2 randomized placebo-controlled trial for COM701 in ovarian cancer and a Phase 1 trial for COM503, with the first patient dosed in Q4 2024 at the START Center for Cancer Research-Midwest.
4
Fair Money & Economic Opportunity
0
Compugen Ltd. is a clinical-stage drug discovery and development company.
1
The provided articles detail its financial performance, clinical trial progress, and partnerships in the pharmaceutical sector. There is no information within the articles pertaining to financial services, lending, or economic opportunity initiatives for underserved populations.
2
Therefore, no KPIs under the 'Fair Money & Economic Opportunity' value can be scored based on the evidence provided.
Fair Pay & Worker Respect
0
No evidence available to assess Compugen Ltd. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
The provided articles, a Reuters summary and a Compugen company description, do not contain any specific, concrete data points or information relevant to Compugen Ltd.'s fair trade and ethical sourcing practices.
1
There is no evidence regarding fair-trade certifications, supplier audit frequencies, instances of forced or child labor, supply chain traceability, remediation processes, ethical clauses in contracts, materials risk, or supplier diversity spend.
2
Therefore, all KPIs related to Fair Trade & Ethical Sourcing must be omitted due to a lack of explicit evidence.
Honest & Fair Business
-40
The company has a formal whistleblower policy and procedures, including a third-party hotline.
1
However, there is no evidence provided regarding independent investigation processes for reports. The company also has an anti-corruption policy that explicitly prohibits bribery, kickbacks, and dealings with sanctioned parties, emphasizing compliance with laws such as the FCPA, False Claims Act, Anti-Kickback Statute, and Israeli law.
2
The evidence does not specify the frequency of training or provide effectiveness metrics for this policy.
Kind to Animals
0
Based on the provided documents, there is insufficient evidence to assess Compugen Ltd.'s alignment with the 'Kind to Animals' value. The company's annual reports and website lack information on animal testing policies, alternative testing methods, or any animal welfare initiatives
1
,
2
,
3
,
4
,
5
,
6
. While one article mentions positive animal model results for a novel peptide
7
,
8
, it does not provide details on the animal species used, the number of animals involved, or the testing protocols. Articles discussing the pharmaceutical industry's general practices and the FDA's policy changes regarding animal testing for monoclonal antibodies do not provide company-specific data
9
,
10
,
11
,
12
,
13
,
14
,
15
,
16
. Without concrete evidence, a neutral score is most appropriate.
No War, No Weapons
0
No evidence available to assess Compugen Ltd. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Compugen Ltd. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles do not contain any specific, concrete data points or evidence relevant to the company's performance on any of the 'Respect for Cultures & Communities' KPIs. All metrics were either explicitly stated as 'Not mentioned' or 'No data relevant to the specified metrics is provided' within the articles.
1
Therefore, no KPIs can be scored based on the available information.
Safe & Smart Tech
0
Compugen's privacy policy states compliance with the CCPA and CAN-SPAM Act.
1
The company also indicates that it retains data only as needed for services or legal reasons.
2
Users and job candidates are provided with rights to access, modify, delete, and restrict their data processing.
3
Zero Waste & Sustainable Products
0
No specific quantitative data for Compugen Ltd. (CGEN.US) regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education is publicly available.
1